EP 217609

Known as: EP-217609, EP217609 
 

Topic mentions per year

Topic mentions per year

2009-2015
01220092015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
EP217609 is a parenteral antithrombotic compound combining in one molecule an indirect anti-factor Xa inhibitor, a direct… (More)
  • figure 1
  • figure 3
  • figure 2
  • table 1
  • table 2
Is this relevant?
2016
2016
Coagulation is an important pathway in the pathophysiology of ischemia-reperfusion injuries. In particular, deceased after… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
EP217609 is a representative of a new class of synthetic parenteral anticoagulants with a dual mechanism of action. It combines… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 3
Is this relevant?
Review
2016
Review
2016
Thrombosis is a complex process involving multiple pathways. Currently, therapy relies on the combination of two or more… (More)
Is this relevant?
2015
2015
EP217609 is a new synthetic parenteral dual-action anticoagulant combining a direct thrombin inhibitor (α-NAPAP analog), an… (More)
Is this relevant?
Review
2015
Review
2015
PURPOSE Heparin anticoagulation followed by protamine reversal is commonly used in cardiopulmonary bypass (CPB) cardiac… (More)
Is this relevant?
2012
2012
EP217609 is a new dual-action parenteral anticoagulant that combines an indirect factor Xa inhibitor (fondaparinux analog) and a… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2012
2012
 
Is this relevant?
Review
2009
Review
2009
The elucidation of the structure of the antithrombin binding sequence in heparin has given a large impulse to the rational design… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?